On September 16, 2021 Herantis Pharma Plc ("Herantis" or the "Company"), an innovative drug development company pioneering new disease modifying and regenerative biologic and gene therapies, reported on 15 September 2021 the result of the offering of new shares (the "Placing Shares") in a private placement to institutional and other qualified investors (the "Placing") (Press release, Herantis Pharma, SEP 16, 2021, View Source;1-346-500-new-shares-registered-with-the-trade-register,c3416563 [SID1234587820]). In the Placing, the Company issued a total of 1,346,500 Placing Shares. The Placing Shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following the registration of the Placing Shares, the total number of registered shares in the Company is 11,103,568. The Placing Shares will be issued in the book-entry system (ISIN code FI4000087861) on or about 20 September 2021. After this, and registration on the investors’ book-entry accounts, they will confer shareholder rights in the Company. The Placing Shares are expected to be ready for delivery to the investors against payment through Euroclear Finland Ltd or, as applicable, through Euroclear Sweden AB on or about 20 September 2021.

Trading in the Placing Shares is expected to commence on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden on or about 20 September 2021.